# Clinical Cases: Renal Pharmacology

## Case 1: Diuretic Resistance in Heart Failure

### Patient Presentation
**Demographics:** 68-year-old male

**Chief Complaint:** Worsening leg swelling despite taking "water pills"

**History of Present Illness:**
The patient has heart failure with reduced ejection fraction (EF 30%) and is on furosemide 80 mg twice daily. Over the past 2 weeks, he has developed progressive lower extremity edema, a 12-pound weight gain, and increased dyspnea on exertion. He reports taking his medications regularly but notes his urine output has decreased.

**Past Medical History:**
- Heart failure with reduced ejection fraction
- Type 2 diabetes mellitus
- CKD Stage 3b (baseline creatinine 2.0 mg/dL)

**Medications:**
- Furosemide 80 mg twice daily
- Carvedilol 25 mg twice daily
- Lisinopril 20 mg daily
- Spironolactone 25 mg daily
- Metformin 500 mg twice daily

**Physical Examination:**
- Blood pressure: 142/88 mmHg
- Heart rate: 82 bpm
- Weight: 98 kg (baseline 86 kg)
- JVP: Elevated to 12 cm
- Lungs: Bibasilar crackles
- Cardiac: S3 gallop
- Extremities: 3+ pitting edema to thighs

### Workup and Results

**Laboratory Studies:**
- Creatinine: 2.4 mg/dL (baseline 2.0)
- BUN: 48 mg/dL
- Potassium: 4.8 mEq/L
- Sodium: 132 mEq/L
- BNP: 1,850 pg/mL (elevated)

### Clinical Image

![Loop Diuretic Mechanism](case_01_image.jpg)

*Diagram illustrating loop diuretic action at the thick ascending limb of the loop of Henle, blocking the NKCC2 transporter and the mechanisms of diuretic resistance including nephron remodeling and distal tubule compensation.*

### Diagnosis
**Acute Decompensated Heart Failure with Diuretic Resistance**

Contributing factors:
- Reduced GFR limiting drug delivery to tubule
- Compensatory distal tubule sodium reabsorption
- Possible poor oral bioavailability from gut edema

### Discussion
This case illustrates diuretic resistance:

- **Loop Diuretics and GFR**: The lecture describes how loop diuretics must reach the tubular lumen to work. In CKD, reduced GFR means less drug delivery; higher doses are needed to achieve effective tubular concentrations.

- **Furosemide Bioavailability**: The lecture notes oral furosemide has only ~50% bioavailability, which worsens with gut edema. IV administration bypasses this limitation.

- **Distal Tubule Compensation**: Chronic loop diuretic use causes hypertrophy of the distal convoluted tubule, increasing sodium reabsorption at this site. Adding a thiazide creates "sequential nephron blockade."

- **Metolazone**: The lecture highlights that metolazone maintains efficacy at very low GFR, making it particularly useful for resistant edema in CKD patients.

### Treatment Plan
1. **IV Diuretic Conversion:**
   - Convert to IV furosemide (doubles effective dose)
   - 80 mg IV bolus, then 80 mg IV every 8 hours
   - OR continuous infusion 10-20 mg/hour

2. **Add Thiazide for Sequential Blockade:**
   - Metolazone 5 mg 30 minutes before furosemide
   - Creates synergistic diuresis

3. **Monitoring:**
   - Daily weights and strict I/O
   - Twice daily electrolytes (risk of profound hypokalemia)
   - Monitor creatinine (may worsen initially)

4. **Adjust Other Medications:**
   - Continue spironolactone (helps prevent hypokalemia)
   - May need to hold lisinopril if creatinine rises >30%

5. **Discharge Plan:**
   - Oral metolazone 2.5-5 mg PRN with furosemide
   - Sodium restriction <2 g/day
   - Daily weights at home

### Teaching Points
1. Loop diuretics block NKCC2 in thick ascending limb (reabsorbs 25% of filtered sodium)
2. Furosemide oral bioavailability is only ~50%; IV doubles effective dose
3. Diuretic resistance involves reduced delivery + distal compensation
4. Metolazone maintains efficacy at very low GFR
5. Sequential nephron blockade (loop + thiazide) overcomes resistance

---

## Case 2: ACE Inhibitor-Associated Complications

### Patient Presentation
**Demographics:** 74-year-old female

**Chief Complaint:** Dry cough and elevated creatinine

**History of Present Illness:**
The patient was started on lisinopril 10 mg daily 3 weeks ago for hypertension with diabetic nephropathy. She has developed a persistent dry cough that keeps her awake at night. Additionally, her creatinine has risen from 1.4 to 1.9 mg/dL. Her potassium is now 5.4 mEq/L.

**Past Medical History:**
- Type 2 diabetes mellitus with nephropathy
- Hypertension
- Peripheral vascular disease

**Current Medications:**
- Lisinopril 10 mg daily (new)
- Amlodipine 5 mg daily
- Metformin 1000 mg twice daily
- Atorvastatin 40 mg daily

**Physical Examination:**
- Blood pressure: 148/82 mmHg
- Heart rate: 72 bpm
- Lungs: Clear (no wheezing)
- Cardiovascular: Regular, bilateral femoral bruits
- No edema

### Workup and Results

**Laboratory Studies (Baseline vs Current):**
- Creatinine: 1.4 → 1.9 mg/dL (36% increase)
- Potassium: 4.6 → 5.4 mEq/L
- BUN: 22 → 32 mg/dL

**Renal Ultrasound with Doppler:**
- Right kidney 9 cm, left kidney 10 cm
- Elevated resistive indices bilaterally
- Cannot exclude renal artery stenosis

### Clinical Image

![ACE Inhibitor Mechanism](case_01_image.jpg)

*Diagram showing how ACE inhibitors cause efferent arteriolar dilation, reducing intraglomerular pressure. In bilateral renal artery stenosis, this compensatory mechanism is essential for maintaining GFR, and its blockade causes acute kidney injury.*

### Diagnosis
**ACE Inhibitor-Related Complications:**
1. ACE inhibitor cough (bradykinin-mediated)
2. AKI likely secondary to bilateral renal artery stenosis
3. Hyperkalemia

### Discussion
This case illustrates ACE inhibitor pharmacology:

- **Cough Mechanism**: The lecture describes how ACE inhibitor cough is due to bradykinin accumulation (ACE breaks down bradykinin). This occurs in 5-20% of patients and is not seen with ARBs.

- **Renoprotective Mechanism**: The lecture explains that ACE inhibitors reduce intraglomerular pressure by blocking efferent arteriolar constriction mediated by angiotensin II. This is beneficial for diabetic nephropathy.

- **Bilateral RAS Contraindication**: The lecture emphasizes that ACE inhibitors are contraindicated in bilateral renal artery stenosis. When renal perfusion is compromised, angiotensin II-mediated efferent constriction is essential to maintain GFR.

- **Acceptable Creatinine Rise**: The lecture states that a creatinine rise up to 30% is acceptable after starting ACE inhibitors. This patient's 36% rise exceeds this threshold and warrants further evaluation.

### Treatment Plan
1. **Discontinue Lisinopril:**
   - Cough should resolve within 1-4 weeks
   - Creatinine should improve

2. **Evaluate for Renal Artery Stenosis:**
   - CT angiography or MRA
   - Consider revascularization if significant stenosis

3. **Alternative Antihypertensive:**
   - If no significant RAS: Can try ARB (no cough)
   - If bilateral RAS confirmed: Avoid all RAAS blockers
   - Consider calcium channel blocker or beta-blocker

4. **Monitor:**
   - Repeat creatinine and potassium in 1 week
   - Watch for hyperkalemia

### Teaching Points
1. ACE inhibitor cough is bradykinin-mediated; switch to ARB if cough intolerable
2. Acceptable creatinine rise after ACE inhibitor is up to 30%
3. ACE inhibitors are contraindicated in bilateral renal artery stenosis
4. Peripheral vascular disease is a risk factor for renal artery stenosis
5. RAAS blockade reduces proteinuria and slows diabetic nephropathy progression

---

## Case 3: SGLT2 Inhibitor Initiation in CKD

### Patient Presentation
**Demographics:** 58-year-old male

**Chief Complaint:** Follow-up for CKD management

**History of Present Illness:**
The patient has CKD Stage 3b due to diabetic nephropathy with persistent albuminuria despite optimal ACE inhibitor therapy. He is referred to discuss additional renoprotective therapy. His diabetes is reasonably controlled on metformin and glipizide.

**Past Medical History:**
- Type 2 diabetes mellitus (15 years, HbA1c 7.4%)
- CKD Stage 3b (eGFR 38 mL/min/1.73m2)
- Hypertension (controlled)

**Current Medications:**
- Lisinopril 40 mg daily
- Metformin 500 mg twice daily
- Glipizide 10 mg twice daily
- Amlodipine 5 mg daily
- Atorvastatin 40 mg daily

**Laboratory Studies:**
- Creatinine: 1.8 mg/dL
- eGFR: 38 mL/min/1.73m2
- Potassium: 4.6 mEq/L
- HbA1c: 7.4%
- Urine albumin-to-creatinine ratio: 580 mg/g

### Clinical Image

![SGLT2 Inhibitor Mechanism](case_01_image.jpg)

*Diagram illustrating the nephroprotective mechanism of SGLT2 inhibitors: blocking glucose and sodium reabsorption in the proximal tubule increases sodium delivery to the macula densa, activating tubuloglomerular feedback, causing afferent arteriolar constriction, and reducing intraglomerular pressure.*

### Diagnosis
**Diabetic Nephropathy with Persistent Albuminuria despite RAAS Blockade**
- CKD Stage G3b, A3 (high risk for progression)
- Candidate for SGLT2 inhibitor therapy

### Discussion
This case illustrates SGLT2 inhibitor renoprotection:

- **Mechanism Beyond Glucose**: The lecture describes how SGLT2 inhibitors provide renoprotection independent of glucose lowering. By blocking sodium-glucose cotransport, they increase sodium delivery to the macula densa, activating tubuloglomerular feedback and reducing intraglomerular pressure.

- **Benefit in Non-Diabetic CKD**: The lecture notes that SGLT2 inhibitors benefit patients with CKD regardless of diabetes status. Trials like DAPA-CKD showed benefit in non-diabetic proteinuric CKD.

- **Expected GFR Dip**: The lecture describes an expected initial GFR dip of 3-5 mL/min when starting SGLT2 inhibitors. This reflects reduced intraglomerular pressure and predicts long-term benefit.

- **Use Despite Low GFR**: Current guidelines support initiating SGLT2 inhibitors down to eGFR 20 mL/min and continuing even lower for renoprotection.

### Treatment Plan
1. **Add SGLT2 Inhibitor:**
   - Dapagliflozin 10 mg daily OR empagliflozin 10 mg daily
   - Can initiate at eGFR >20 mL/min

2. **Patient Education:**
   - Expect initial small GFR drop (3-5 mL/min) - this is beneficial
   - Genital mycotic infections common (maintain hygiene)
   - Drink adequate fluids
   - Hold during sick days (dehydration, major surgery)

3. **Monitoring:**
   - Creatinine in 2-4 weeks (expect small rise)
   - Assess for volume depletion
   - Watch for UTI/genital infection symptoms

4. **Medication Adjustments:**
   - May need to reduce glipizide dose (reduced hypoglycemia risk is low)
   - Continue metformin (still appropriate at this GFR)
   - Continue ACE inhibitor (synergistic benefit)

### Teaching Points
1. SGLT2 inhibitors activate tubuloglomerular feedback, reducing intraglomerular pressure
2. Renoprotection is independent of diabetes status
3. Expected initial GFR dip of 3-5 mL/min predicts long-term benefit
4. Main adverse effects: genital mycotic infections, volume depletion
5. Can initiate at eGFR >20 mL/min; continue for renoprotection even lower

---

## Image Reference

For visual reference of renal pharmacology concepts, see:
- Radiopaedia: [Diuretics](https://radiopaedia.org/articles/diuretics) - Mechanisms
- Wikimedia Commons: [Nephron](https://commons.wikimedia.org/wiki/Category:Nephrons) - Sites of drug action
- Wikipedia: [SGLT2 inhibitor](https://en.wikipedia.org/wiki/SGLT2_inhibitor) - Mechanism and clinical use

---

## Learning Points

1. **Loop Diuretic Site**: Block NKCC2 in thick ascending limb; account for 25% of sodium reabsorption

2. **Furosemide Bioavailability**: Only 50% oral; IV doubles effective dose

3. **ACE Inhibitor Contraindications**: Bilateral renal artery stenosis, pregnancy, angioedema history

4. **Acceptable Creatinine Rise**: Up to 30% after ACE inhibitor initiation; higher suggests RAS

5. **SGLT2 Mechanism**: Tubuloglomerular feedback activation reduces intraglomerular pressure; benefit independent of glucose lowering